DNA flow cytometry as a surrogate end-point in patients with superficial bladder cancer treated with 4-HPR

Eur J Cancer Prev. 1994 Jul;3(4):377-9. doi: 10.1097/00008469-199407000-00017.
No abstract available

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Aneuploidy
  • DNA, Neoplasm / analysis*
  • Diploidy
  • Feasibility Studies
  • Female
  • Fenretinide / adverse effects
  • Fenretinide / therapeutic use*
  • Flow Cytometry*
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Pilot Projects
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / genetics
  • Urinary Bladder Neoplasms / pathology*

Substances

  • DNA, Neoplasm
  • Fenretinide